Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas

doi:10.3748/wjg.v25.i14.1684

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7182)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

422

WORD

211

HTML

4817

Figures (1-4)

198

Tables (1-3)

152

Sum=5800

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

617

Download

765

Sum=1382

Apr 14, 2019 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Apr 14, 2019; 25(14): 1684-1696
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684

Full Size Figure Download Figure

Figure 3 Kaplan–Meier survival analysis of the gastric neuroendocrine carcinomas patients. A: Patients with high infiltration of CD8⁺ lymphocytes tended to have a relative longer survival, but the difference was not statistically significant; B: Kaplan-Meier overall survival curves in patients with high and low expression of programmed death ligand 1 (PD-L1) in the whole population; C: Low PD-1⁺ cell infiltration group; D: High PD-1⁺ cell infiltration group. PD-L1: Programmed death ligand 1.

Citation: Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696
URL: https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i14.1684